SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 16: 688696.
  • 2
    Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol. 1992; 10: 414421.
  • 3
    Haarstad H, Jacobsen AB, Schjolesth SA, Risberg T, Fossa SD. Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study. Ann Oncol. 1994; 5: 245248.
  • 4
    Hofmockel G, Langer W, Theiss W, Gruss A, Frohmuller HGW. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol. 1996; 156: 1821.
  • 5
    Van Herpen CM, Jansen RL, Kruit WH, et al. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter Phase II study. Dutch Immunotherapy Working Party. Br J Cancer. 2000; 82: 772776.
  • 6
    Sella A, Kilbourn RG, Gray I, et al. Phase I study of interleukin-2 combined with interferon-α and 5-fluorouracil in patients with metastatic renal cell carcinoma. Cancer Biother. 1994; 9: 103111.
  • 7
    Hanninen EL, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol. 1996; 155: 1925.
  • 8
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207219.
  • 9
    Atzpodien J, Kirchner H, Hanninen EL, et al. European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol. 1993; 20: 2226.
  • 10
    Scheffe H. The analysis of variance. New York: John Wiley & Sons, 1995.
  • 11
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 12
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 13
    Frank IN, Graham SD, Nabors WL. Urologic and male genital cancer. In: HollebAI, FinkDJ, eds. Clinical oncology, 1st ed. Atlanta: American Cancer Society, 1994: 271289.
  • 14
    Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the cytokine working group study. Cancer J Sci Am. 1997; 3: 157162.
  • 15
    Facendola G, Locatelli MC, Pizzocaro G, et al. Subcutaneous administration of interleukin-2 and inteferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer. 1995; 72: 15311535.
  • 16
    Rogers E, Bredin H, Butler M, et al. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the multicentre All Ireland Immunotherapy Study Group. Eur Urol. 2000; 37: 3726137266.
  • 17
    Atzpodien J, Korfe A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet. 1990; 335: 15091512.
  • 18
    Atzpodien J, Hanninen EL, Kirchner H, et al. Multi-institutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995; 13: 497501.
  • 19
    Sella A, Logothetis CJ, Fitz K, et al. Phase II study of interferon-α and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol. 1992; 147: 573577.
  • 20
    Pectasides D, Varthalitis J, Kostopoulou M, et al. An outpatient Phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer. Oncology. 1998; 55: 1015.
  • 21
    Revaud A, Audhuy B, Gomez F, et al. Subcutaneous interleukin-2, interferon alfa-2a and continuous infusion of fluorouracil in metatatic renal cell carcinoma: a multicenter Phase II trial. Group Francais de L'immunotherapie. J Clin Oncol, 1998; 16: 27282732.
  • 22
    Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg. 1992; 127: 13431349.
  • 23
    Sella A, Swanson DA, Ro JY, et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol. 1993; 149: 1921.
  • 24
    Cerfolio RJ, Allen MS, Deschamps C, et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 1994; 57: 339344.
  • 25
    Kierney PC, Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol. 1994; 1: 345352.
  • 26
    Samland D, Steinbach F, Reiher F, Schmidt U, Gruss A, Allhoff EP. Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in treatment of metastatic renal cell cancer. Eur Urol. 1999; 35: 204209.
  • 27
    Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology. 2000; 55: 3640.
  • 28
    Fallick ML, McDermott DF, La Rock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 1997; 158: 16911695.
  • 29
    Belldegrun AS, Zisman A, Pantuck AJ, Grititz BJ, Figlin RA. Aggressive surgical resection and immunotherapy improves survival of patients with metastatic renal cell carcinoma: the UCLA experience 1989-1999 [abstract 2458]. ASCO 2001. [http://www.asco.org/asco/ascoMainConstructor/1,47468,_12|002326|00_29|00A|00_18|002001|00_19|002458,00.asp]
  • 30
    Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358: 966970.
  • 31
    Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med. 2001; 345: 16551659.